This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pfizer Inc.

Drug Names(s): dexrazoxane hydrochloride

Description: Zinecard is a sterile, pyrogen-free lyophilizate intended for intravenous administration. It is a cardioprotective agent for use in conjunction with doxorubicin. The active substance, dexrazoxane, is an antidote to anthracyclines. The way it works is not entirely clear, but may be linked to the way the medicine attaches to iron in the body to form a chelate and to its effect on some enzymes, such as topoisomerase II. Some evidence suggests that dexrazoxane inhibits topoisomerase II reversibly.

Deal Structure: Pharmacia and Pfizer
In July 2002, Pfizer and Pharmacia jointly announced that they have signed a definitive agreement providing for Pfizer to acquire Pharmacia in a stock-for-stock transaction valued at $60 billion. The acquisition closed in April 2003.

Zinecard News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug